A Novel Way to Quantify Schizophrenia Symptoms in Clinical Trials
aut.relation.articlenumber | e13398 | en_NZ |
aut.relation.issue | 3 | en_NZ |
aut.relation.journal | European Journal of Clinical Investigation | en_NZ |
aut.relation.volume | 51 | en_NZ |
aut.researcher | Sandham, Margaret | |
dc.contributor.author | Medvedev, ON | en_NZ |
dc.contributor.author | Berk, M | en_NZ |
dc.contributor.author | Dean, OM | en_NZ |
dc.contributor.author | Brown, E | en_NZ |
dc.contributor.author | Sandham, MH | en_NZ |
dc.contributor.author | Dipnall, JF | en_NZ |
dc.contributor.author | McNamara, RK | en_NZ |
dc.contributor.author | Sumich, A | en_NZ |
dc.contributor.author | Krägeloh, CU | en_NZ |
dc.contributor.author | Narayanan, A | en_NZ |
dc.contributor.author | Siegert, RJ | en_NZ |
dc.date.accessioned | 2021-06-08T01:36:30Z | |
dc.date.available | 2021-06-08T01:36:30Z | |
dc.date.copyright | 2021 | en_NZ |
dc.date.issued | 2021 | en_NZ |
dc.description.abstract | BACKGROUND: A major problem in quantifying symptoms of schizophrenia is establishing a reliable distinction between enduring and dynamic aspects of psychopathology. This is critical for accurate diagnosis, monitoring and evaluating treatment effects in both clinical practice and trials. MATERIALS AND METHODS: We applied Generalisability Theory, a robust novel method to distinguish between dynamic and stable aspects of schizophrenia symptoms in the widely used Positive and Negative Symptom Scale (PANSS) using a longitudinal measurement design. The sample included 107 patients with chronic schizophrenia assessed using the PANSS at five time points over a 24-week period during a multi-site clinical trial of N-Acetylcysteine as an add-on to maintenance medication for the treatment of chronic schizophrenia. RESULTS: The original PANSS and its three subscales demonstrated good reliability and generalisability of scores (G=0.77-0.93) across sample population and occasions making them suitable for assessment of psychosis risks and long-lasting change following a treatment, while subscales of the five factor models appeared less reliable. The most enduring symptoms represented by the PANSS were poor attention, delusions, blunted affect, and poor rapport. More dynamic symptoms with 40-50% of variance explained by patient transient state including grandiosity, preoccupation, somatic concerns, guilt feeling and hallucinatory behaviour. CONCLUSIONS: Identified dynamic symptoms are more amendable to change and should be the primary target of interventions aiming at effectively treating schizophrenia. Separating out the dynamic symptoms would increase assay sensitivity in trials, reduce the signal to noise ratio and increase the potential to detect the effects of novel therapies in clinical trials. | en_NZ |
dc.identifier.citation | European Journal of Clinical Investigation, 51(3), e13398. | |
dc.identifier.doi | 10.1111/eci.13398 | en_NZ |
dc.identifier.issn | 0014-2972 | en_NZ |
dc.identifier.issn | 1365-2362 | en_NZ |
dc.identifier.uri | https://hdl.handle.net/10292/14249 | |
dc.language | eng | en_NZ |
dc.publisher | Wiley | en_NZ |
dc.relation.uri | https://onlinelibrary.wiley.com/doi/10.1111/eci.13398 | |
dc.rights | © 2020 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | |
dc.rights.accessrights | OpenAccess | en_NZ |
dc.subject | Clinical Trial | en_NZ |
dc.subject | Generalisability Theory | en_NZ |
dc.subject | Measurement | en_NZ |
dc.subject | Positive and Negative Syndrome Scale | en_NZ |
dc.subject | Schizophrenia | en_NZ |
dc.title | A Novel Way to Quantify Schizophrenia Symptoms in Clinical Trials | en_NZ |
dc.type | Journal Article | |
pubs.elements-id | 391762 | |
pubs.organisational-data | /AUT | |
pubs.organisational-data | /AUT/Faculty of Design & Creative Technologies | |
pubs.organisational-data | /AUT/Faculty of Design & Creative Technologies/School of Engineering, Computer & Mathematical Sciences | |
pubs.organisational-data | /AUT/Faculty of Design & Creative Technologies/School of Engineering, Computer & Mathematical Sciences/Centre for Artificial Intelligence Research | |
pubs.organisational-data | /AUT/Faculty of Health & Environmental Science | |
pubs.organisational-data | /AUT/Faculty of Health & Environmental Science/School of Clinical Sciences | |
pubs.organisational-data | /AUT/Faculty of Health & Environmental Science/School of Clinical Sciences/Nursing Department | |
pubs.organisational-data | /AUT/Faculty of Health & Environmental Science/School of Clinical Sciences/Psychology & Neuroscience Department | |
pubs.organisational-data | /AUT/PBRF | |
pubs.organisational-data | /AUT/PBRF/PBRF Design and Creative Technologies | |
pubs.organisational-data | /AUT/PBRF/PBRF Design and Creative Technologies/PBRF ECMS | |
pubs.organisational-data | /AUT/PBRF/PBRF Health and Environmental Sciences | |
pubs.organisational-data | /AUT/PBRF/PBRF Health and Environmental Sciences/HH Clinical Sciences 2018 PBRF | |
pubs.organisational-data | /AUT/PBRF/PBRF Health and Environmental Sciences/HY Public Health & Psychosocial Studies 2018 PBRF |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- A novel way to quantify schizophrenia symptoms in clinical trials.pdf
- Size:
- 156.99 KB
- Format:
- Adobe Portable Document Format
- Description:
- Journal article
License bundle
1 - 1 of 1
Loading...
- Name:
- AUT Grant of Licence for Tuwhera Aug 2018.pdf
- Size:
- 276.29 KB
- Format:
- Adobe Portable Document Format
- Description: